Shares in Novocure (NSDQ:NVCR) rose today after the FDA granted its Tumor Treating Fields delivery system a humanitarian use device designation as a treatment for pleural mesothelioma. The humanitarian use designation is the 1st step in winning a humanitarian device exemption, which would allow Novocure to makrket TTFields in combination with chemotherapy as a treatment for […]
NovoCure
Novocure touts quality of life data for Optune, chemo combo
Novocure (NSDQ:NVCR) touted health-related quality of life analyses from a pivotal Phase III trial combining its Optune device with standard temozolomide chemotherapy for patients with newly diagnosed glioblastoma. The data showed that adding Optune to temozolomide did not negatively impact health-related quality of life, except for itchy skin which the company attributed to skin irritation […]
NovoCure launches 2 pediatric trials of TTFields
NovoCure (NSDQ:NVCR) said today it is launching 2 pilot trials exploring the use of tumor treating fields to treat pediatric patients with high grade gliomas. The St. Helier, N.J.-based company produces the Optune, a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer […]
NovoCure shares rise on Q1 EPS beat
Shares in NovoCure (NSDQ:NVCR) rose today after the medical device maker beat losses per share expectations on Wall Street with its 1st quarter earnings results. The St. Helier, Jersey-based company posted losses of $18 million, or 21¢ per share, on sales of $34.9 million for the 3 months ended March 31, seeing bottom-line losses shrink 49.1% […]
Novocure gains on additional Optune data
Shares in Novocure (NSDQ:NVCR) are on the rise again after the company today cited additional data from a pivotal trial evaluating its Optune device with temozolomide chemotherapy as a treatment for newly-diagnosed glioblastoma. Novocure’s Optune mobile device delivers low-intensity, intermediate frequency, alternating electric fields, called “tumor treating fields” or TTFields, to inhibit cancer cell replication. Get […]
Novocure touts long-term data for Optune, chemo combination therapy for glioblastoma
Shares in Novocure (NSDQ:NVCR) jumped nearly 50% today after the company touted 5-year data today from the Phase III pivotal EF-14 trial evaluating its Optune device with temozolomide chemotherapy for the treatment of newly-diagnosed glioblastoma. Data from 695 patients show a consistent and maintained improvement in overall survival at 2, 3, 4 and 5 years, […]
Japan clears Novocure’s 2nd gen Optune device
Novocure (NSDQ:NVCR) said today it won approval from the Japanese Ministry of Health, Labour and Welfare for its 2nd-gen Optune device. The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death, the St. Helier, N.J.-based company […]
Novocure enrolls 1st patient in TTFields, chemo treatment lung cancer phase III trial
Novocure (NSDQ:NVCR) said today it enrolled the 1st patient in the phase 3 pivotal Lunar trial of its Tumor Treating Field technology for treating patients with advanced non-small cell lung cancer who have failed platinum-based therapy. The prospective, randomized 512-patient trial from the St. Helier, N.J.-based company aims to test the safety and efficacy of its TTFields […]
Japan approves Novocure’s Optune brain cancer treatment
Novocure (NSDQ:NVCR) said today that the Japanese Ministry of Health, Labor and Welfare has approved its tumor treating fields delivery system, Optune, for adult patients with supra-tentorial glioblastoma following surgery and radiation therapy. The St. Helier, N.J.-based company is expected to submit an application for public reimbursement of the device in Japan for newly diagnosed […]
Novocure touts positive TTFields data for pancreatic, ovarian cancer
Novocure (NSDQ:NVCR) shares were up 6% after hours yesterday after the company released positive data for its “tumor treating fields” combined with chemotherapy for pancreatic and ovarian cancer. The St. Helier, N.J.-based company’s TTFields are low-intensity, alternating electric fields meant to inhibit cancer cell replication and cause cell death. Novocure presented data from its phase II […]
NovoCure touts long-term analysis for Optune TTF, drug combo in brain cancer
NovoCure (NSDQ:NVCR) today released long-term analysis data from the phase 3 pivotal EF-14 trial of its Optune device in combination with temozolomide for treating newly diagnosed glioblastoma, touting superior survival results. Data from the trial indicated superior 2, 3 and 4-year survival rates for patients treated with the combined therapy over temozolomide alone. Data from the […]